Roos Marcel, Richart Tom, Kouznetsova Tatiana, von Eynatten Maximilian, Lutz Jens, Heemann Uwe, Baumann Marcus, Staessen Jan A
Department of Nephrology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Regul Pept. 2009 Apr 10;154(1-3):39-43. doi: 10.1016/j.regpep.2008.12.001. Epub 2008 Dec 13.
To evaluate the association between fetuin-A level (AHSG), its encoding gene (Thr256Ser) and arterial function in subjects with normal kidney function.
The aortic pulse wave velocity (aPWV) is a predictor for cardiovascular mortality. Fetuin-A is a calcification inhibitor and correlates negatively with increased vascular stiffness in dialysis patients. The fetuin-A polymorphism (Thr256Ser) is associated with reduced fetuin levels and accelerated vascular calcification in dialysis patients. Little is known about the role of fetuin-A as an independent predictor for the development of arterial stiffness in healthy subjects.
We studied 116 subjects with normal kidney function (age 47+/-12 years, 50 females and 66 males) of the FLEMENGHO study. Calcium measurements, plasma fetuin-A, its encoding gene (Thr256Ser) and indexes of arterial stiffness, such as aPWV and arterial distensibility, were determined.
Fetuin-A levels were negatively correlated with aPWV (r=-0.21, p=0.029). After an adjustment for multiple covariables, fetuin-A levels were independently associated with aPWV (r=-0.30, p=0.022) in males but not in females. Male fetuin-A SerSer carrier had lower fetuin-A levels and higher aPWV (fetuin-A: 61.9+/-29.0 microg/ml; aPWV: 14.3+/-0.9 m/s) as compared to ThrThr (fetuin-A: 109.9+/-54.9 microg/ml; aPWV: 6.4+/-1.3 m/s) and ThrSer carrier (fetuin-A: 100.8+/-52.5 microg/ml; aPWV: 6.6+/-1.3 m/s). Other calcium variables were not significantly associated with arterial stiffness.
With respect to common calcium variables, only fetuin-A level showed an inverse relation with aPWV in men with normal renal function. Male fetuin-A SerSer carriers demonstrate particularly high aortic stiffness, possibly implying a status of increased cardiovascular risk.
评估正常肾功能受试者中胎球蛋白-A水平(AHSG)、其编码基因(Thr256Ser)与动脉功能之间的关联。
主动脉脉搏波速度(aPWV)是心血管死亡率的一个预测指标。胎球蛋白-A是一种钙化抑制剂,与透析患者血管僵硬度增加呈负相关。胎球蛋白-A多态性(Thr256Ser)与透析患者胎球蛋白水平降低及血管钙化加速有关。关于胎球蛋白-A作为健康受试者动脉僵硬度发展的独立预测指标的作用,人们了解甚少。
我们研究了FLEMENGHO研究中的116名肾功能正常的受试者(年龄47±12岁,女性50名,男性66名)。测定了钙含量、血浆胎球蛋白-A、其编码基因(Thr256Ser)以及动脉僵硬度指标,如aPWV和动脉扩张性。
胎球蛋白-A水平与aPWV呈负相关(r = -0.21,p = 0.029)。在对多个协变量进行调整后,胎球蛋白-A水平在男性中与aPWV独立相关(r = -0.30,p = 0.022),而在女性中则不然。与ThrThr(胎球蛋白-A:109.9±54.9微克/毫升;aPWV:6.4±1.3米/秒)和ThrSer携带者(胎球蛋白-A:100.8±52.5微克/毫升;aPWV:6.6±1.3米/秒)相比,男性胎球蛋白-A SerSer携带者的胎球蛋白-A水平较低,aPWV较高(胎球蛋白-A:61.9±29.0微克/毫升;aPWV:14.3±0.9米/秒)。其他钙变量与动脉僵硬度无显著关联。
就常见的钙变量而言,在肾功能正常的男性中,只有胎球蛋白-A水平与aPWV呈负相关。男性胎球蛋白-A SerSer携带者表现出特别高的主动脉僵硬度,这可能意味着心血管风险增加的状态。